about
CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma.L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial.Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapyHuman papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer of unknown primary origin.Galectins and urological cancer.Galectin-3 and metastasis.Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone.Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.Health insurance status and survival among patients with head and neck cancer in Japan.Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.Implication of galectin-3 in Wnt signaling.Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways.Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs.Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis.Risk factors associated with competing mortality among patients with head and neck cancer in Japan.Factors predicting severe infections during chemotherapy in head and neck cancer patients.A Case of Skull Base Osteomyelitis with Multiple Cerebral Infarction.Gram staining for the treatment of peritonsillar abscessPhase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.Synchronous bilateral tonsillar carcinomas associated with human papillomavirus.Chemoradiation therapy for squamous cell carcinoma of the external auditory canal: A meta-analysis.[Head and neck soft tissue sarcoma].Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: A meta-analysis.Age-adjusted Charlson Comorbidity Index predicts prognosis of laryngopharyngeal cancer treated with radiation therapy.Pretreatment serum lactate dehydrogenase as a prognostic indicator for oral cavity squamous cell carcinoma.Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.[A Case of Hereditary Medullary Thyroid Cancer (MEN2A/FMTC) Diagnosed at the Time of Recurrence].Limitation of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (FDG-PET) to detect early synchronous primary cancers in patients with untreated head and neck squamous cell cancer.Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies.[A case of laryngeal necrosis following concurrent chemoradiotherapy for advanced hypopharyngeal cancer after insertion of a nasogastric tube].Prognostic significance of serum squamous cell carcinoma antigen in patients with head and neck cancer.Factors associated with malnutrition in patients with head and neck cancer[Clinical analysis of cervical lymph node metastasis from an unknown primary carcinoma].Prognostic significance of body mass index before treatment for head and neck cancer[Treatment outcome and failure pattern of olfactory neuroblastoma: a clinical analysis of 14 cases and meta-analysis of Japanese cases]Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis
P50
Q33994280-0F9C82C4-558B-4F23-B77A-97B2C71DEA20Q34626107-A5436C15-FF68-4E68-9583-9FC6FF8E0536Q34998582-389704A5-2D5A-440F-B7E9-B1AF43EF6144Q35154020-6901EAEB-DC50-4F33-9ECF-E26E3FD7C5DBQ35613240-C49F9573-35C4-416E-8D7D-C67E9BD677C1Q35646658-188F5415-D70C-4172-A8F2-6BD98B892C59Q36195978-BAECB85E-3255-4E7A-AC73-7EA24D98F7E8Q38365707-4A29E499-8DA0-41DB-B5BB-B47DF963E99BQ38639725-F9E95DAE-BC48-4FB1-A5D0-F0928D239C1EQ40140669-DA79A220-DC9D-488B-ACC2-AE41AFB3C362Q40304129-0FE8D657-FF55-4D1D-AD79-0BC804AC93AEQ40345366-065A0710-41AC-4DEB-A36A-FAAB3B5B45E4Q40377941-AA6ADD22-AC8D-417E-A9AD-1185F1C6FC44Q40427814-583987A8-636B-4373-8DC6-B8FC7165667BQ40554460-D854F235-1B07-4E27-9CD5-4CAF2DB1BF29Q40560449-23E97AC8-85E6-48FB-9563-36FA752B3FF8Q41035366-A01369C1-BD10-423B-A96F-D61A3DC5C424Q41075136-5A8F4494-1E59-4054-A77C-4EEF87BE4FFFQ41137401-0BBE875B-89BE-4E4E-9241-2F3BC39A1F63Q41226530-C7E591E3-EB86-47E2-8251-873E39102378Q41842852-008EFA40-B87A-4F56-9E63-D116453EA3D9Q42151129-536A5D6E-EC89-4935-B614-207012ED73ECQ42282693-FF98F500-B90F-4C6E-A7AF-E1A43C7E5E66Q44224357-BD83E0D7-E21E-43AD-8712-FB2629460D93Q45737509-89A75281-01B7-4F2F-BFC5-6D4614373365Q48117100-15E540D6-2652-493C-8FB3-0183D165DD30Q48122486-5D6E7D32-FFF6-4A8E-9AB9-A69D1BE04D12Q48131770-5A9C1FD1-A060-4E36-9032-44180264ED1FQ50848240-CC66C8B2-EF17-4A23-B353-D8CB3A5AC478Q52991095-5F7ED4C6-E827-4017-96B8-1A911BBEB899Q53097347-0BE27107-843F-4ACC-B93E-987506E6E792Q53452227-880ECF5C-A273-428C-8494-31ABC0849732Q54660487-E8841049-BB4A-443D-A49F-F5F5643D288BQ55058835-1AAA19E2-0DB8-476A-8689-2127F67204EDQ58084060-6B1245E1-4872-47E2-B02D-306CF5BE3589Q64967655-9F69FD42-DE63-4BC6-B881-8419010321A0Q88008744-0C6CC08D-F524-4E4F-999B-EDD895334611Q88136770-5407EFD9-3771-4D48-B43F-BF432C740EBAQ90917816-99EE37D9-478D-4C7F-8931-E9E3DB153FE5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yukinori Takenaka
@ast
Yukinori Takenaka
@en
Yukinori Takenaka
@es
Yukinori Takenaka
@sl
type
label
Yukinori Takenaka
@ast
Yukinori Takenaka
@en
Yukinori Takenaka
@es
Yukinori Takenaka
@sl
prefLabel
Yukinori Takenaka
@ast
Yukinori Takenaka
@en
Yukinori Takenaka
@es
Yukinori Takenaka
@sl
P106
P1153
7102054128
P21
P31
P496
0000-0002-3135-5635
P569
2000-01-01T00:00:00Z